Purchase this article with an account.
Agathe Cazet-Supervielle, Michèle Boissonnot, Sahbi Rouissi, Nicolas Leveziel; Intravitreal injections of ranibizumab with deferred laser grid laser photocoagulation for the treatment of diabetic macular edema with visual impairment: results at 1 year of LLOMD study. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1772.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The diabetic macular edema (DME) is the most common cause of central visual loss in diabetic patients. Intravitreal injections (IVT) of ranibizumab have been approved for the treatment of DME. However, around 10 ranibizumab IVTs are needed during the first year of treatment with ranibizumab alone (RESOLVE study). In this context, ranibizumab IVTs combined with macular laser may be beneficial to reduce the number of IVT. The aim of this study was to evaluate the efficacy of IVT associated with deferred laser grid for diabetic macular edema. The primary endpoint was the number of reinjections, the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) measured at one year, of a strategy based on intravitreal ranibizumab injection associated with laser treatment in DME.
Prospective, monocentric open-label, uncontrolled phase 2 study. 15 eyes of 14 patients with BCVA ≤ 69 letters and CRT ≥ 310μ (OCT Cirrus Zeiss) due to DME were enrolled between October 2011 and October 2012. Patients were treated with ranibizumab 0.5 mg given for 3 months then with laser grid at month 4. During follow-up, a ranibizumab injection was performed every 2 months in case of BCVA decreased more than 5 letters. Each patient in the study underwent VA measurement on the Early Treatment Diabetic Retinopathy Study chart (ETDRS), spectral domain-OCT, quality of life scale, glycated hemoglobin (HbA1c) measurement, fluorescein angiography, and multifocal electroretinogram at baseline and during their follow-up.
The mean age of the subjects was 62 years old. At baseline, their characteristics were (expressed as mean): duration of diabetes: 15 years, HbA1c: 7,4%, VA: 52 letters (20/100 snellen equivalent), CRT: 475,6μ. From baseline at 12 months, there is a mean gain of 9,8 letters of BCVA (p = 0.013). The decrease in the average CRT is 55,3μ (p = 0.0425). 40% of patients didn’t require a new IVT at 12 months. No endophthalmitis cases occurred.
Adding macular grid to ranibizumab IVT appears promising in the treatment of DME. It seems to reduce the number of IVTs and consequently the economic burden of the treatment
This PDF is available to Subscribers Only